Otsuka Pharmaceutical Development & Commercialization, Inc. clinical trials

A subsidiary of Otsuka Holdings Co., Ltd.

The registry lists 293 studies whose lead sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc.. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 293. List all 293 → · All Otsuka Holdings Co., Ltd. studies →

• A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)RecruitingNCT04782258Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study of JNT-517 in Participants With Phenylketonuria (PKU)RecruitingNCT06971731Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the BodyRecruitingNCT07525960Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07767903Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07786454Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsNot yet recruitingNCT07455084Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)Not yet recruitingNCT07770815Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the BodyRecruitingNCT07649265Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS)AvailableNCT07862959

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingNCT07861113Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderRecruitingNCT07759128Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationRecruitingNCT07759154Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered TogetherRecruitingNCT07446400Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney FunctionRecruitingNCT07713758Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisRecruitingNCT07209761Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)Enrolling by invitationNCT05248659Phase 2/3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Long-Term Study of JNT-517 in Participants With PhenylketonuriaRecruitingNCT06628128Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney TissueRecruitingNCT06740526Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentCompletedNCT02153502Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderCompletedNCT00095823Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaActive, not recruitingNCT06894212Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaTerminatedNCT03896945Phase 2/3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male AdultsTerminatedNCT07329621Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBCompletedNCT05221502Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)CompletedNCT00365859Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)Active, not recruitingNCT06799520Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaCompletedNCT05781399Phase 1/2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)Active, not recruitingNCT05248646Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00201994Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderCompletedNCT00095758Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• "SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaCompletedNCT00072683Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Switch Study of BMS-337039 in Schizophrenic Out-patientsCompletedNCT00232687Phase 4

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Rebamipide Eye Drops to Treat Dry EyeCompletedNCT00201955Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and AdolescentsCompletedNCT00102479Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04092686Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a PlaceboCompletedNCT00201981Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and WomenCompletedNCT07542847Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With SchizophreniaCompletedNCT00706654Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954CompletedNCT06937593Phase 1

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaCompletedNCT04072354Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity DisorderCompletedNCT01939353Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.CompletedNCT05279313Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive DisorderCompletedNCT05536414Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed EpisodeCompletedNCT00277212Phase 4

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma PatientsCompletedNCT01009840Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).CompletedNCT00332241Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Safety, Tolerability and Efficacy of AVP-786 for the Treatment of DisinhibitionTerminatedNCT02534038Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaCompletedNCT06637514Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)CompletedNCT00337571Phase 3

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.

• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaCompletedNCT02477670Phase 2

  Sponsor listed in the registry: Otsuka Pharmaceutical Development & Commercialization, Inc.